Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
LUPulmonx Corporation logo

Pulmonx Corporation (LUNG)

NASDAQ Global Select · Currency in USD
$1.83 ▼ -0.05 (-2.66%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.83 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$1.88
Open
$1.85
Day's Range
$1.79 – $1.86
52 Week Range
$1.13 – $2.89
Volume
227,761
Avg. Volume
482,415
Market Cap
$78.60M
Beta (5Y Monthly)
0.28
PE Ratio (TTM)
--
EPS (TTM)
-$1.14
Earnings Date
Oct 27, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$10.00

Profile: Pulmonx Corporation

Sector
Healthcare
Industry
Medical - Devices
Full-time employees
296
CEO
Glendon E. French

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System.

Earnings

Next report: Tue, Oct 27, 2026
EPS estimate -$0.26 · Revenue est. $21.93M
DateEst.Actual
Jul 29, 2026-$0.28-$0.24Beat
Apr 29, 2026-$0.33-$0.33Beat
Mar 4, 2026-$0.39-$0.25Beat
Nov 12, 2025-$0.40-$0.34Beat
Jul 30, 2025-$0.40-$0.38Beat
Apr 30, 2025-$0.37-$0.36Beat

Analyst view

Consensus price target
$10.00 ▲ +446.4%
Range $2.50 – $20.00
Rating: Buy
Buy 44% · Hold 44% · Sell 11%

Get free alerts on LUNG and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.